Application
Filed 2022-05-13 · Abandoned The official file ↗ · Art unit 1638 · Examiner Robert M Kelly Easy · CPC A61K 48/005 · Wuhan Neurophth Biotechnology Limited Company · Wuhan Neurophth Biotechnology Limited Company
In context
Rejections and RCEs are averages per allowed application for the examiner and the unit; months run from filing.
| Rejections | RCEs | Months to first action | Months to a decision | Outcome | |
|---|---|---|---|---|---|
| This application | 0 | 0 | 31.2 | 40.0 | Abandoned |
| Robert M Kelly its examiner | 1.9 | 0.44 | 19.0 | 34.7 | 71% allowed |
| Art unit 1638 | 1.3 | 0.12 | 21.7 | 31.2 | 78% allowed |
Indicative value
Where a routine asset in its field starts, moved by what the record shows about this one: the term left, where the field is heading, how hard it was tested and what the owner spent on it.
| Step | Effect | Why |
|---|---|---|
| Starting range | $30,000 to $250,000 | A routine granted US patent in Software and data processing, sold through a broker. An assumption, not a quote. |
| Term left | ×0.96 | About 11 years of term left, counting twenty years from this filing date. |
| Where the field is heading | ×1.18 | Its share of new filings is rising. |
| How scarce a grant is | ×1.06 | Fewer applications are allowed here than across the office. |
| What the owner spent on it | ×1.16 | The owner paid for two requests for continued examination. |
| Indicative range | $41,000 to $340,000 | The starting range times every adjustment, rounded. |
An indicative range read from the record, not an appraisal. The claims are not read, and evidence of use, family members abroad, licenses and maintenance fees are not in the record: each can move a real price more than everything shown here. The starting range is an assumption for a routine granted US patent in a brokered sale; a buyer whose product the claims block can pay several times more.
PATLY.AI